Biaryl kinase inhibitors

Patent metadata

Field	Value
Publication number	US-10155760-B2
Application number	US-201815865848-A
Country	US
Kind code	B2
Filing date	Jan 9, 2018
Priority date	Apr 2, 2014
Publication date	Dec 18, 2018
Grant date	Dec 18, 2018

Abstract

The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

First claim

The invention claimed is:

1. A composition comprising a pharmaceutically acceptable amount of (S)-1-((2′,6-bis(difluoromethyl)-[2,4′-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

2. A method for treating or managing a disease or a disorder mediated by AAK1 activity, the method comprising administering to a patient in need thereof a therapeutically effective amount of (S)-1-((2′,6-bis(difluoromethyl)-[2,4′-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine, or a pharmaceutically acceptable salt thereof, wherein a disease or disorder mediated by AAKI activity is pain.

3. The method of claim 2 wherein the pain is neuropathic pain.

4. The method of claim 3 wherein the neuropathic pain is fibromyalgia or peripheral neuropathy.

Assignees

• Bristol Myers Squibb Co

Inventors

• Luo Guanglin
• Dzierba Carolyn Diane
• Macor John E

Classifications

• C07D213/34

  to which a second hetero atom is attached · CPC title

• C07D213/74 Primary

  Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals · CPC title

• C07D237/08

  with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms · CPC title

• C07D413/10

  linked by a carbon chain containing aromatic rings · CPC title

• C07D401/04

  directly linked by a ring-member-to-ring-member bond · CPC title